• Image of a coronavirus particle.
    Coronavirus visualisation

Welcome to AVID-CC trial website!

Full study title: Adalimumab in COVID-19 to prevent respiratory failure in community care.


COVID-19 is caused by a virus called SARS-CoV-2. Most (8 out of 10) people with the disease have only mild symptoms, but in some people the condition can be severe and even fatal. Patients who develop severe disease tend to have a lot of inflammation – a process in which the immune system goes into overdrive and may cause damage as well as fighting the virus.

We have been funded by the Wellcome Trust to investigate whether a treatment called anti-TNF (which has been in use for many years for inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease) can reduce inflammation in COVID-19 and therefore reduce the progression of COVID-19 to more severe disease, in people in community care. People who are residents of community care facilities have been particularly hard hit by COVID-19 and so we are conducting the study to see if the treatment works in this group. A company called Sandoz will be providing the medication (Adalimumab) for the trial.


Please note the AVID-CC trial has now closed.